Longest survival follow-up ever reported for immunotherapy treatment in this setting
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Global Phase-3 study initiation expected in the second half of 2024
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Combination shows consistent benefit across prespecified post-progression outcomes
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
Subscribe To Our Newsletter & Stay Updated
